In September 2026, news broke that Insilico Medicine's drug, rentosertib, had undergone testing in a cohort of 42 patients diagnosed with idiopathic pulmonary fibrosis (IPF). The average age of these patients was 67. Remarkably, after just four weeks of treatment, six distinct aging biomarkers, developed by various research teams, indicated that the patients' biological ages had regressed by an average of 3 to 4 years. Some patients even exhibited a reversal of nearly 6 years in their biological age.

AI technology played a pivotal role throughout the drug's development process, from the initial discovery of therapeutic targets to the intricate molecular design. Rentosertib has now successfully advanced to Phase III clinical trials. Alex Zhavoronkov, the visionary founder of Insilico Medicine, hailed this achievement as their most significant publication to date.

Originally conceived as a treatment for IPF, researchers also delved into rentosertib's potential to intervene in the aging process. Their findings revealed that the optimal dosage for enhancing lung function did not coincide with that required to reverse aging signals. Furthermore, they observed that alterations in patients' blood proteins ran counter to the typical trajectory of aging.

By adopting an aging-centric approach to target identification and subsequently developing drugs for associated diseases, Insilico Medicine is bolstering longevity research through its disease-focused endeavors. Leveraging AI technology alongside China's robust R&D and clinical infrastructure, the company is pioneering a sustainable pathway for anti-aging research, heralding a new era in the quest for extended human healthspan.